Mohammed A M Osman1. 1. General Organization for Teaching Hospitals and Institutes, Egypt.
Abstract
PURPOSE: This phase II trial was designed to assess the response rate, survival benefits and toxicity profile of temozolomide, and brain reirradiation using conformal radiotherapy (RT) for treatment of recurrent high grade glioma. DESIGN: Open-label phase II trial. PATIENTS: Twenty-nine patients had been enrolled in the study between February 2006 and June 2009. Patients had to show unequivocal evidence of tumour recurrence on gadolinium-enhanced magnetic resonance imaging (MRI) after failing conventional RT with or without temozolomide and surgery for initial disease. Histology included recurrent anaplastic astrocytoma, glioblastoma multiforme. INTERVENTIONS: Patients were treated by temozolomide at a dose of 200 mg/m(2)/day for chemonaïve patients, and at a dose of 150 mg/m(2)/day to previously treated patients, for 4-5 cycles. Then, patients underwent reirradiation by conformal RT at a dose of 30-40 Gy by conventional fractionation. MAIN OUTCOME MEASURES: The primary end point of the study was response. The secondary end points included survival benefit. RESULTS: All the 29 patients were treated with temozolomide and reirradiation. Two patients achieved complete remission (CR), 4 achieved partial remission (PR), with an overall objective response rate of 20.6%, and further 10 patients had stable disease (SD), with a SD rate of 34.4%. The mean progression free survival (PFS) was 10.1 months, and the mean overall survival (OS) was 11.4 months. Additionally, treatment significantly improved quality of life (QOL). Treatment was tolerated well with mild grade 1, 2 nausea/vomiting in 40% of cycles, and mild grade 1, 2 haematological toxicities (neutropenia/thrombocytoprnia) in 8.6% of cycles. CONCLUSIONS: Temozolomide and conformal RT had an anti-tumor activity in recurrent high grade glioma, and represented a good treatment hope for patients with recurrent brain glioma.
PURPOSE: This phase II trial was designed to assess the response rate, survival benefits and toxicity profile of temozolomide, and brain reirradiation using conformal radiotherapy (RT) for treatment of recurrent high grade glioma. DESIGN: Open-label phase II trial. PATIENTS: Twenty-nine patients had been enrolled in the study between February 2006 and June 2009. Patients had to show unequivocal evidence of tumour recurrence on gadolinium-enhanced magnetic resonance imaging (MRI) after failing conventional RT with or without temozolomide and surgery for initial disease. Histology included recurrent anaplastic astrocytoma, glioblastoma multiforme. INTERVENTIONS:Patients were treated by temozolomide at a dose of 200 mg/m(2)/day for chemonaïve patients, and at a dose of 150 mg/m(2)/day to previously treated patients, for 4-5 cycles. Then, patients underwent reirradiation by conformal RT at a dose of 30-40 Gy by conventional fractionation. MAIN OUTCOME MEASURES: The primary end point of the study was response. The secondary end points included survival benefit. RESULTS: All the 29 patients were treated with temozolomide and reirradiation. Two patients achieved complete remission (CR), 4 achieved partial remission (PR), with an overall objective response rate of 20.6%, and further 10 patients had stable disease (SD), with a SD rate of 34.4%. The mean progression free survival (PFS) was 10.1 months, and the mean overall survival (OS) was 11.4 months. Additionally, treatment significantly improved quality of life (QOL). Treatment was tolerated well with mild grade 1, 2 nausea/vomiting in 40% of cycles, and mild grade 1, 2 haematological toxicities (neutropenia/thrombocytoprnia) in 8.6% of cycles. CONCLUSIONS:Temozolomide and conformal RT had an anti-tumor activity in recurrent high grade glioma, and represented a good treatment hope for patients with recurrent brain glioma.
Authors: T Veninga; H A Langendijk; B J Slotman; E H Rutten; A J van der Kogel; M J Prick; A Keyser; R W van der Maazen Journal: Radiother Oncol Date: 2001-05 Impact factor: 6.280
Authors: M J van den Bent; F Keime-Guibert; A A Brandes; M J Taphoorn; J M Kros; F A Eskens; A F Carpentier Journal: Neurology Date: 2001-07-24 Impact factor: 9.910
Authors: Jennifer A Quinn; David A Reardon; Allan H Friedman; Jeremy N Rich; John H Sampson; James M Provenzale; Roger E McLendon; Sridharan Gururangan; Darell D Bigner; James E Herndon; Nicholas Avgeropoulos; Jonathan Finlay; Sandra Tourt-Uhlig; Mary Lou Affronti; Brandon Evans; Valerie Stafford-Fox; Sara Zaknoen; Henry S Friedman Journal: J Clin Oncol Date: 2003-02-15 Impact factor: 44.544
Authors: Jörg van den Boom; Marietta Wolter; Rork Kuick; David E Misek; Andrew S Youkilis; Daniel S Wechsler; Clemens Sommer; Guido Reifenberger; Samir M Hanash Journal: Am J Pathol Date: 2003-09 Impact factor: 4.307
Authors: Michael D Prados; W K Alfred Yung; Howard A Fine; Harry S Greenberg; Larry Junck; Susan M Chang; M Kelly Nicholas; H Ian Robins; Minesh P Mehta; Karen L Fink; Kurt A Jaeckle; John Kuhn; Kenneth R Hess; S Clifford Schold Journal: Neuro Oncol Date: 2004-01 Impact factor: 12.300
Authors: W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin Journal: Br J Cancer Date: 2000-09 Impact factor: 7.640
Authors: A Baehr; D Trog; M Oertel; S Welsch; K Kröger; O Grauer; U Haverkamp; H T Eich Journal: Strahlenther Onkol Date: 2020-02-03 Impact factor: 3.621
Authors: Jennifer Clarke; Elizabeth Neil; Robert Terziev; Philip Gutin; Igor Barani; Thomas Kaley; Andrew B Lassman; Timothy A Chan; Josh Yamada; Lisa DeAngelis; Ase Ballangrud; Robert Young; Katherine S Panageas; Kathryn Beal; Antonio Omuro Journal: Int J Radiat Oncol Biol Phys Date: 2017-06-30 Impact factor: 7.038
Authors: Neil K Taunk; Fabio Y Moraes; Freddy E Escorcia; Lucas Castro Mendez; Kathryn Beal; Gustavo N Marta Journal: Expert Rev Anticancer Ther Date: 2016-02-09 Impact factor: 4.512